Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIII
27 sept. 2022 08h00 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the...
Oyster Point Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 sept. 2022 17h36 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the...
Oyster Point Pharma to Present Analyses at the Women in Ophthalmology Summer Symposium
25 août 2022 08h00 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization...
Oyster Point Pharma To Attend H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17, 2022
15 août 2022 08h00 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the...
Oyster Point Pharma To Report Second Quarter 2022 Financial Results On August 11, 2022
08 août 2022 16h03 HE
|
Oyster Point Pharma, Inc.
Conference Call and Webcast Scheduled for August 11, 2022, 4:30 p.m. ET PRINCETON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST) a commercial-stage...